Norway· NO-ID_86FE85A1-5C4B-4C08-8BFE-03FCCD8EB29E
Rydapt
A midostaurin product containing midostaurin, registered in Norway by Novartis Europharm Limited (1). The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Midostaurin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EX10 (midostaurin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Midostaurin · ATC L01EX10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Midostaurin
- Manufacturer
- Novartis Europharm Limited (1)
- Country
- Norway (NO)
- ATC code
- L01EX10
- ATC class
- Midostaurin
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_86FE85A1-5C4B-4C08-8BFE-03FCCD8EB29E
- no_varenummer5197552 x 28NOK 85015.1
- no_varenummer500476112NOK 169994
- gtin7612797493892
- gtin7612797360187
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
582 interactions on record for midostaurin.
Graded by severity as the source publishes them — 132 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Midostaurin · interactions on record
582 records
- 132 severe
- 445 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Midostaurin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandRydaptNovartis Europharm Limited
- CzechiaRYDAPTNovartis Europharm Limited, Dublin
- SwitzerlandRydapt 25 mg, WeichkapselnNovartis Pharma Schweiz AG
- United StatesRYDAPTNovartis Pharmaceuticals Corporation
- IcelandRydaptNovartis Europharm Limited*
- PolandRydaptNovartis Europharm Limited
- SwedenRydapt 25 mg Kapsel, mjukNovartis Europharm Limited
- FranceRYDAPT 25 mg, capsule molleNOVARTIS EUROPHARM (IRLANDE)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Rydapt
- Liechtenstein · Rydapt
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e16fc2df-e254-4cf3-ab1f-6a9fb1f0e9a5 GET /v1/drugs/e16fc2df-e254-4cf3-ab1f-6a9fb1f0e9a5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsel, myk",
"source": "fest",
"status": "A",
"atc_name": "Midostaurin",
"merkevare_id": "ID_86FE85A1-5C4B-4C08-8BFE-03FCCD8EB29E",
"name_form_strength": "Rydapt kaps 25 mg",
"prescription_group": "C"
}See everything about midostaurin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.